Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

Gastric Inhibitory Peptide (22-51) (human) TFA

😃Good
Catalog No. T83710
Alias Glucose-dependent Insulinotropic Peptide (22-51), GIP (22-51)

Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.

Gastric Inhibitory Peptide (22-51) (human) TFA

Gastric Inhibitory Peptide (22-51) (human) TFA

😃Good
Catalog No. T83710Alias Glucose-dependent Insulinotropic Peptide (22-51), GIP (22-51)
Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$55InquiryInquiry
5 mg$256InquiryInquiry
10 mg$483InquiryInquiry
25 mg$1,130InquiryInquiry
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.
SynonymsGlucose-dependent Insulinotropic Peptide (22-51), GIP (22-51)
Chemical Properties
Molecular Weight3181.60
FormulaC140H226N44O41.XCF3COOH
SmilesOC(C(F)(F)F)=O.O=C(O)CC[C@H](N[H])C(N[C@@H](CCCCN[H])C(N[C@@H](CCCCN[H])C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CC1=CNC=N1)C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N2CCC[C@H]2C(N[C@@H](CO)C(N[C@H](C(N3CCC[C@H]3C(N[C@@H](C(C)C)C(NCC(N[C@@H](CO)C(N[C@@H](CC4=CNC=N4)C(N[C@H](C(N[C@@H](CCCCN[H])C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N5CCC[C@H]5C(N[C@@H](CCC(N)=O)C(N6CCC[C@H]6C(N[C@@H](CCCNC(N)=N)C(NCC(N7CCC[C@H]7C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)CC(C)C)=O)=O)=O)CC(C)C)=O)C)=O)=O)CC8=CC=CC=C8)=O)=O)=O)=O)=O)=O
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: Soluble

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Gastric Inhibitory Peptide (22-51) (human) TFA | purchase Gastric Inhibitory Peptide (22-51) (human) TFA | Gastric Inhibitory Peptide (22-51) (human) TFA cost | order Gastric Inhibitory Peptide (22-51) (human) TFA | Gastric Inhibitory Peptide (22-51) (human) TFA chemical structure | Gastric Inhibitory Peptide (22-51) (human) TFA formula | Gastric Inhibitory Peptide (22-51) (human) TFA molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.